The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.
|Videos|June 22, 2020
A 68-Year-Old Man With Gastrointestinal Stromal Tumor
Author(s)Margaret von Mehren, MD
Margaret von Mehren, MD, describes the rationale for treating a man with GIST with ripretinib as fourth-line therapy.
Advertisement
Case: A 68-Year-Old Man With Gastrointestinal Stromal Tumor
Initial presentation
- A 68-year-old man complains of a 5-month history early satiety and vague abdominal pain
- PMH: hypertension, medically controlled; colonoscopy at age 55 unremarkable; no family history of cancer
- PE: diffuse abdominal pain on palpation; otherwise unremarkable
Clinical workup
- Labs: Hb 10.1 g/dL, plt 100 x 109/L; other lab values WNL
- Endoscopy: showeda submucosal ~ 5 cm mass with ulceration
- EUS-FNA biopsy: irregular borders on extraluminal surfaces of the stomach with evidence of heterogeneous echogenicity
- Biopsy showed gastrointestinal tumor with mitotic activity showed >5 mitoses/50 HPFs
- Abdominal/pelvic CT confirmed a 5.4 cm lesion in the body of the stomach
- MRI showed evidence of peritoneal metastases
- IHC and genetic mutational analysis: KIT exon 11 mutation
- ECOG 0
Treatment
- He was started on imatinib 400 mg PO qDay, continued for 26 months until he complained of increased abdominal pain and decreased appetite
- ECOG 1; Imatinib was discontinued due to progressive disease
- Treatment with sunitinib 50 mg PO qDay for 4 weeks, with a 2-week drug-free interval was started
- Treatment was well tolerated for 9 cycles when he developed an altered sense of taste, occasional vomiting and diarrhea; sunitinib was discontinued
- Regorafenib 160 mg (four 40 mg tablets) PO qDay for the first 21 days of each 28-day cycle was started and tolerated except for hand-foot syndrome
- Regorafenib was discontinued on progression of disease
- The patient was started on ripretinib 150 mg PO qDay
Advertisement
Related to this article
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
The NDA was completed for first-line zipalertinib plus platinum chemotherapy in EGFR exon 20 insertion NSCLC, based on phase 3 REZILIENT3 data showing improved PFS.
Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.
Advertisement
Advertisement
Trending on Targeted Onc
1
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
2
Referral Before Salvage Therapy Keeps CAR T an Option in Myeloma
3
FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL
4
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
5